Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Traws Pharma, Inc. - Common Stock (NQ:TRAW)

1.482 -0.008 (-0.51%)
Streaming Delayed Price Updated: 2:23 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Traws Pharma, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Announces Up to $60 Million Private Placement Financing
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
From Traws Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
Via Investor Brand Network
News headline image
Annovis Appoints Mark Guerin as Chief Financial Officer
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside!
Via AB Newswire
News headline image
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Reports Full Year 2024 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Announces Management Updates
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
From Traws Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.